156 related articles for article (PubMed ID: 27196139)
1. Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
van Helden EJ; Hoekstra OS; Boellaard R; Roth C; Mulder ER; Verheul HM; Menke-van der Houven van Oordt CW
PLoS One; 2016; 11(5):e0155178. PubMed ID: 27196139
[TBL] [Abstract][Full Text] [Related]
2. Early
Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
[TBL] [Abstract][Full Text] [Related]
3. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
Liu FY; Yen TC; Wang JY; Yang TS
Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
[TBL] [Abstract][Full Text] [Related]
4.
Fledelius J; Winther-Larsen A; Khalil AA; Bylov CM; Hjorthaug K; Bertelsen A; Frøkiær J; Meldgaard P
J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
[TBL] [Abstract][Full Text] [Related]
5. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Johannesen HH; Nielsen D; Schou JV; Jensen BV; Høgdall EV; Hendel HW
Cancer Med; 2014 Oct; 3(5):1294-301. PubMed ID: 24941936
[TBL] [Abstract][Full Text] [Related]
6. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
[TBL] [Abstract][Full Text] [Related]
7. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
8. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
Di Fabio F; Pinto C; Rojas Llimpe FL; Fanti S; Castellucci P; Longobardi C; Mutri V; Funaioli C; Sperandi F; Giaquinta S; Martoni AA
Gastric Cancer; 2007; 10(4):221-7. PubMed ID: 18095077
[TBL] [Abstract][Full Text] [Related]
10. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
11. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
Berger AK; von Gall C; Abel U; Delorme S; Kloor M; Ose J; Weber TF; Stange A; Haag GM; Haberkorn U; Lordick F; Jäger D
BMC Cancer; 2012 Mar; 12():108. PubMed ID: 22439666
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
13. Combining
Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
[TBL] [Abstract][Full Text] [Related]
14. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
15. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
16. Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
Woff E; Salvatore L; Marmorino F; Genovesi D; Critchi G; Guiot T; Ameye L; Sclafani F; Hendlisz A; Flamen P
J Nucl Med; 2022 Apr; 63(4):549-555. PubMed ID: 34326124
[TBL] [Abstract][Full Text] [Related]
17. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
18. Correlation between KRAS mutation and
Cho A; Jo K; Hwang SH; Lee N; Jung M; Yun M; Hwang HS
Abdom Radiol (NY); 2017 Jun; 42(6):1621-1626. PubMed ID: 28161825
[TBL] [Abstract][Full Text] [Related]
19. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
[TBL] [Abstract][Full Text] [Related]
20. The value of
Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
